Table 1.

Short-term achievement of MDA in patients with PsA treated with anti–TNF-α therapies.

Biologic Agent	Trial	Week	Anti-TNF Status of Patient Population	n	Dose	Patients with MDA, %	Reference
Randomized Controlled Trials
IFX	IMPACT	16	Anti–TNF-naive	31	5 mg/kg	48^*	Coates LC, et al, 2010¹⁵
	IMPACT	16	Anti–TNF-naive	32	PBO	3
	IMPACT 2	24	Anti–TNF-naive	77	5 mg/kg	52^†
	IMPACT 2	24	Anti–TNF-naive	80	PBO	21
CZP	RAPID-PsA	24	Anti–TNF-naive and -experienced	138	200 mg	33^†	Mease PJ, et al, 2014¹⁷
				135	400 mg	34^†
				136	PBO	6
GOL	GO-REVEAL	14	Anti–TNF-naive	285	50 mg/100 mg	24^*	Kavanaugh A, et al, 2016¹⁸
GOL	GO-REVEAL	14	Anti–TNF-naive	104	PBO	1	Kavanaugh A, et al, 2016¹⁸
ADA	ADEPT	24	Anti–TNF-naive	62	40 mg	39^†	Mease PJ, et al, 2013¹⁶
ADA	ADEPT	24	Anti–TNF-naive	60	PBO	7	Mease PJ, et al, 2013¹⁶
Open-label Trial
IFX	RESPOND	16	Anti–TNF-naive	57	5 mg/kg + MTX	59^#	Baranauskaite A, et al, 2012²⁰
IFX	RESPOND	16	Anti–TNF-naive	58	MTX 15 mg	24	Baranauskaite A, et al, 2012²⁰

↵* p < 0.0001 vs PBO;
↵† p < 0.001 vs PBO;
↵# p < 0.05 vs MTX. TNF: tumor necrosis factor; PsA: psoriatic arthritis; ADA: adalimumab; CZP: certolizumab pegol; GOL: golimumab; IFX: infliximab; MDA: minimal disease activity; MTX: methotrexate; PBO: placebo.